18:52 , Mar 29, 2019 |  BC Week In Review  |  Company News

Guardant Health to acquire fellow cancer diagnostic company Bellwether Bio

Liquid biopsy company Guardant Health said it will advance its early detection product pipeline by acquiring Bellwether Bio for an undisclosed sum. Bellwether Bio Inc. (Seattle, Wash.) is developing cancer diagnostics based on the epigenomics...
02:20 , Jan 18, 2019 |  BC Innovations  |  Targets & Mechanisms

Exploring 3-D genomic white space

Gene regulation is offering a new class of targets that operate on a higher level than DNA sequences and epigenetic markers: 3-D genomic structures. While strategies to drug the 3-D genome are still in their...
21:12 , Feb 22, 2018 |  BC Innovations  |  Finance

Bigger BRAIN Initiative

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is preparing to push projects in three areas past the pilot phase with $169 million in new NIH grants announced in 4Q17. The aim is to...
17:56 , Apr 28, 2017 |  BC Week In Review  |  Company News

Epigenomics, Cathay Fortune deal

Cathay's Blitz F16-83 GmbH subsidiary will acquire molecular diagnostics company Epigenomics for €7.52 per share, or about €171 million ($185.6 million) in cash. The price is a 52% premium on Epigenomics' closing price of €4.95...
22:38 , Apr 26, 2017 |  BC Extra  |  Company News

Chinese PE firm to acquire Epigenomics

A subsidiary of Chinese private equity firm Cathay Fortune International Co. Ltd. will acquire molecular diagnostics company Epigenomics AG (Xetra:ECX; OTCQX:EPGNY) for €7.52 per share, or about €171 million ($185.6 million) in cash. The subsidiary,...
00:06 , Dec 3, 2016 |  BC Extra  |  Company News

Management tracks

Prescription and OTC pharma Taro Pharmaceutical Industries Ltd. (NYSE:TARO) said Uday Baldota will replace Kal Sundaram as its CEO, effective April 2017. Baldota is EVP and CFO at Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA). Abhay...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
01:06 , Jul 1, 2016 |  BC Extra  |  Company News

Management tracks

Molecular diagnostics company Epigenomics AG (Xetra:ECX) named Gregory Hamilton CEO. He replaces CEO and CFO Thomas Taapken, who has left the company. Hamilton was CEO at AltheaDx Inc. (San Diego, Calif.). The company expects to...
07:00 , May 2, 2016 |  BC Week In Review  |  Company News

Epigenomics sales and marketing update

Epigenomics and Polymedco Inc. (Cortlandt Manor, N.Y.) launched Epigenomics’ Epi proColon blood-based colorectal cancer screening test in the U.S. The second-generation test is based on detection of methylated DNA of the septin 9 gene in...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Clinical News

Epi proColon regulatory update

FDA approved a PMA from Epigenomics for its Epi proColon blood-based colorectal cancer screening test. Epigenomics and Polymedco Inc. (C ortlandt Manor, N.Y.) will jointly market Epi proColon in the U.S. The test is indicated...